Dose escalation of TAS-117 in patients with advanced solid tumors.

A phase 1b/2 open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer

PROMETCO study: Metastatic colorectal cancer (mCRC) treatment patterns of the first 531 enrolled patients

Phase 1b study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma

Futuximab/Modotuximab plus Trifluridine/Tipiracil versus Trifluridine/Tipiracil in KRAS/NRAS and BRAF Wild Type (WT) metastatic colorectal cancer previously treated with both standard and anti-EGFR treatment